Minerva Neurosciences, Inc. (NERV)
Recent Filing Index
| Form | Filed | Qtr End | F_Period | 8K: Earnings Release |
|---|---|---|---|---|
| 10-QLatest | Q2-2026 | 8-K (2026-08-07) · 99.1 | ||
| 10-Q | Q1-2026 | 8-K (2026-05-05) · 99.1 | ||
| 10-KLatest | FY-2025 | 8-K (2026-03-11) · 99.1 | ||
| 10-Q | Q3-2025 | — | ||
| 10-Q | Q2-2025 | — | ||
| 10-Q | Q1-2025 | — | ||
| 10-K/A | FY-2024 | |||
| 10-K/A | FY-2024 | |||
| 10-K | FY-2024 | — | ||
| 10-Q | Q3-2024 | — | ||
| 10-Q | Q2-2024 | — | ||
| 10-Q | Q1-2024 | — | ||
| 10-K/A | FY-2023 | |||
| 10-K/A | FY-2023 | |||
| 10-K | FY-2023 | — | ||
| 10-Q | Q3-2023 | — | ||
| 10-K/A | FY-2022 |
Filing Summary
| Report Name | Notes | Fiscal Period (Annual) | Fiscal Period (Quarter) |
|---|---|---|
| Document and Entity Information | ||
| Statements | ||
| Consolidated Balance Sheets | ||
| Consolidated Balance Sheets (P) | ||
| Consolidated Statements of Operations | ||
| Consolidated Statements of Redeemable Preferred Stock and Stockholders' Deficit | ||
| Consolidated Statements of Stockholders' (deficit) Equity | ||
| Consolidated Statements of Stockholders' Deficit | ||
| Consolidated Statements of Cash Flows | ||
| Notes | ||
| Accrued Expenses and Other Liabilities | ||
| Commitments and Contingencies | ||
| Cybersecurity Risk Management, Strategy, and Governance | — |
|
| Income Taxes | — |
|
| Insider Trading Arrangements | ||
| Insider Trading Policies and Procedures | — |
|
| Nature of Operations and Liquidity | ||
| Net (loss) Income Per Share of Common Stock | ||
| Net Income (loss) Per Share of Common Stock | ||
| Net Loss Per Share of Common Stock | ||
| Pay Vs Performance Disclosure | ||
| Redeemable Preferred Stock and Stockholders' Deficit | ||
| Related Party Transactions | ||
| Sale of Future Royalties | ||
| Significant Accounting Policies | ||
| Stock Award Plan and Stock-based Compensation | ||
| Stockholders' Deficit | ||
| Stockholders' Equity | ||
| Subsequent Events | ||
| Warrant Liability | ||